To determine the effects of 12 weeks administration of different dose levels of ALV003 on the mucosal lining of the small intestine and symptoms in celiac disease patients.

Inclusion Criteria:

• Ages 18 to 80 years
• Physician diagnosed celiac disease
• Adherence to a gluten-free diet
• Experiencing symptoms of celiac disease over a 1-month period
• Willing to take study medication for 12 weeks
• Willing to comply with all study procedures
• Sign informed consent

Exclusion Criteria:

• Active inflammatory bowel disease
• Active dermatitis herpetiformis
• Use of certain specific medications prior to entry
• History of alcohol or illicit drug abuse in previous 6 months
• Pregnant or lactating
• Received any experimental drug within 30 days of enrollment
• Uncontrolled chronic disease or condition